ARCHIVES

Clinical Trial Pathology Improvements Recommended By Group Remaining Actions After Merit Review

This article is from The Cancer Letter archive.

Vol. 05 No. 02 | January 12, 1979

Download PDF Visit The Full Archive

Related Articles

Clolar Approved for Pediatric Refractory/Relapsed ALL

January 28, 2005

Letter to The Editor: IOM Panel Urges Greater Integration Of Research

February 12, 1999

Harkin, Bumpers Concerned Over Centers Funding

May 5, 1989

In Brief: Newell Tells Advisory Committee It Isn’t a Lobbying Group, “Accept What We Give You”

April 8, 1977

In Brief: Clarke, Einstein Lead ACCC; Changes At CCSG, Cohen Leaves USC For Childhood Foundation

April 17, 1992

In Brief: FASEB Recommends $11.75 Billion NIH Budget; Natcher Wins House Appropriations Chairmanship

December 11, 1992